Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Carbogen, Nextpharma Link Drug Services
by Michael McCoy
October 12, 2009
| A version of this story appeared in
Volume 87, Issue 41
Carbogen Amcis and NextPharma Technologies are forming an alliance to combine Carbogen’s highly potent active pharmaceutical ingredient (API) manufacturing capabilities in Switzerland with NextPharma’s dosage-form drug-manufacturing services, which it offers from seven sites across North America and Europe. API manufacturer Lonza seeks to create a similar combined service through its planned acquisition of Patheon (C&EN, Aug. 31, page 10).
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter